Use of markers of bone turnover for monitoring bone metastases and the response to therapy

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 54-59

  Lipton, Allan ^a   Costa, Luis ^a,b   Ali, Suhail ^a,b   Demers, Laurence ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN; CREATININE; DEOXYPYRIDINOLINE; PAMIDRONIC ACID; PEPTIDE; PYRIDINIUM DERIVATIVE; PYRIDINOLINE; ZOLEDRONIC ACID;

BONE METASTASIS; BONE RADIOGRAPHY; BONE REMODELING; BONE SCINTISCANNING; BONE TURNOVER; CANCER PAIN; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034857236     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25438     Document Type: Conference Paper

References (12)

1. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease
2. Biochemical markers of bone turnover in patients with metastatic bone disease
3. Serum ostase in the follow-up of breast cancer patients
4. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma
5. Biochemical picture of bone metabolism in breast cancer patients with bone metastases
6. Biochemical markers of bone turnover correlate with the extent of metastatic bone disease
7. Elevated serum N-telopeptide (NTX) predicts poor prognosis in breast cancer patients with bone metastases
8. Relationship between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease
9. Markers of bone resorption in patients treated with pamidronate
10. Assessment of bone response to systemic therapy in an EORR trial: Preliminary experience with the use of collagen cross-link excretion
11. Correlation of urinary N-telopeptide and ICTP levels with progression of bone metastases: A prospective study
12. Biochemical markers and skeletal metastases